| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 91.0K |
| Gross Profit | -91.0K |
| Operating Expense | 5,548.0K |
| Operating I/L | -5,548.0K |
| Other Income/Expense | 828.0K |
| Interest Income | 920.0K |
| Pretax | -4,720.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -4,720.0K |
Benitec Biopharma Inc. is a biotechnology company specializing in the development of DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. The company's main focus is on developing gene therapy agents such as BB-301 for treating oculopharyngeal muscular dystrophy and BB-103 for chronic hepatitis B virus infection.